Achondroplasia is a type of dwarfism that affects the growth in children, leading to a short stature or small size. Achondroplasia is a rare genetic condition that affects one in every 15,000 to ...

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial. Hypochondroplasia is a form of skeletal ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin reported a strong quarter, and Voxzogo still has ample ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net income was up a robust 525% year over year, rising to $125 million.